MINORITY TYPE 1 DIABETES REGISTRY

描述：(改编自《调查者摘要》)此应用程序 要求继续进行以人口为基础的大型登记册 非裔美国人和美国人中的胰岛素依赖型糖尿病(IDDM) 芝加哥的西班牙裔儿童。书记官处项目平均包括49个 非洲裔美国人案件和每年20起西班牙裔事件案件。这 是来自非洲的病例数量的三倍多 世界上任何其他登记处，以及#年拉美裔病例数量最多的 美国大陆。调查员将利用书记官处进行调查 下面是两个直接相关的问题。 1.IDDM自然历史上的种族差异：最近的关注 重点关注一些年轻人最初被诊断出患有 IDDM实际上是糖尿病的一种变种。到目前为止，还没有基于人口的 有关于美国年轻人糖尿病疾病谱的数据。 考虑到非裔和非裔美国人患NIDDM的风险很高 拉美裔，很可能有独特的遗传和/或病理生理 接受胰岛素治疗的少数民族儿童的工作过程。调查人员 假设临床上的非典型疾病将在 接受胰岛素治疗的少数民族患者中有相当大比例(5%-15%)，以及 它可以根据家庭与自身免疫性糖尿病区分开来 病史、发病特征和遗传标记。 2.少数群体中的IDDM结果：研究人员最近证明 芝加哥IDDM的病死率是 非洲裔美国人比非西班牙裔白人患者长达24岁，而且 也是发病率差异的一些证据。他们的假设是 在控制持续时间的情况下，早期发展迹象的速度 登记的少数族裔患者的并发症将大大超过 在其他地方报告的非西班牙裔白人患者中也有这种情况。他们会 调查非洲裔美国人患者的死亡率 在芝加哥的西班牙裔患者中，如果两者的死亡率 非洲裔美国人和西班牙裔患者的比例超过了其他地方公布的比例。 他们将完成以下具体任务：1)继续 芝加哥市少数族裔儿童IDDM发病率登记； 2)确定以下人群中非典型糖尿病的患病率 胰岛素治疗，青年发病患者；3)构建一个分数来预测 年轻少数民族患者非典型糖尿病的后续临床病程； 和4)描述糖尿病并发症和死亡率的自然病史 在患有IDDM的少数族裔青年中。

DESCRIPTION: (Adapted from Investigator's Abstract) This application requests continuation of the large population-based registry of insulin-dependent diabetes mellitus (IDDM) among African-American and Hispanic children in Chicago. The Registry project includes on average 49 African-American cases and 20 Hispanic incident cases per year. This represents more than three times the number of African-origin cases than in any other registry worldwide, and the largest number of Hispanic cases in the continental US. The investigators will use the Registry to investigate two questions of immediate relevance, as follow. 1. Ethnic differences in the natural history of IDDM: Recent attention has focused on the possibility that some young people initially diagnosed with IDDM actually have a variant form of diabetes. To date, no population-based data are available on the spectrum of diabetic disease in U.S. youth. Considering the high risk of NIDDM among both African-American and Hispanics, there may well be unique genetic and/or pathophysiologic processes at work in insulin-treated minority children. The investigators hypothesize that clinically atypical disease will be described in a substantial proportion (5-15%) of insulin-treated minority patients, and that it can be distinguished from autoimmune diabetes on the basis of family history, onset characteristics, and genetic markers. 2. IDDM outcomes among minorities: The investigators recently demonstrated that the case-fatality rate for IDDM in Chicago is nine times greater among African-American than non-Hispanic white patients through age 24, and there is some evidence of disparities in morbidity as well. They hypothesize that, controlled for duration, the rates of early signs of developing complications in registered minority patients will significantly exceed those reported elsewhere among non-Hispanic white patients. They will investigate whether the mortality rate among African-American patients exceeds that among Hispanic patients in Chicago, and if mortality among both African-American and Hispanic patients exceed published rates elsewhere. They will accomplish the following specific tasks: 1) continue the incidence registry of IDDM among minority children in the City of Chicago; 2) determine the prevalence of atypical diabetes among these insulin-treated, youth onset patients; 3) construct a score to predict the subsequent clinical course of atypical diabetes in young minority patients; and 4) describe the natural history of diabetes complications and mortality in minority young people with IDDM.